These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Inhibition of rat liver and duodenum soluble catechol-O-methyltransferase by a tight-binding inhibitor OR-462. Schultz E; Nissinen E Biochem Pharmacol; 1989 Nov; 38(22):3953-6. PubMed ID: 2597177 [TBL] [Abstract][Full Text] [Related]
7. Structure-based drug design of catechol-O-methyltransferase inhibitors for CNS disorders. Ma Z; Liu H; Wu B Br J Clin Pharmacol; 2014 Mar; 77(3):410-20. PubMed ID: 23713800 [TBL] [Abstract][Full Text] [Related]
8. A semiempirical study on inhibition of catechol O-methyltransferase by substituted catechols. Ovaska M; Yliniemelä A J Comput Aided Mol Des; 1998 May; 12(3):301-7. PubMed ID: 9749372 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of catechol-O-methyltransferase by N-(3,4-dihydroxyphenyl) maleimide. Piedrafita FJ; Elorriaga C; Fernández-Alvarez E; Nieto O J Enzyme Inhib; 1990; 4(1):43-50. PubMed ID: 2128841 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies. Chen D; Wang CY; Lambert JD; Ai N; Welsh WJ; Yang CS Biochem Pharmacol; 2005 May; 69(10):1523-31. PubMed ID: 15857617 [TBL] [Abstract][Full Text] [Related]
12. COMT-dependent protection of dopaminergic neurons by methionine, dimethionine and S-adenosylmethionine (SAM) against L-dopa toxicity in vitro. Werner P; Di Rocco A; Prikhojan A; Rempel N; Bottiglieri T; Bressman S; Yahr MD Brain Res; 2001 Mar; 893(1-2):278-81. PubMed ID: 11223018 [TBL] [Abstract][Full Text] [Related]
13. Crystal Structure of Catechol O-Methyltransferase Complexed with Nitecapone. Iijima H; Takebe K; Suzuki M; Kobayashi H; Takamiya T; Saito H; Niwa N; Kuwada-Kusunose T Chem Pharm Bull (Tokyo); 2020; 68(5):447-451. PubMed ID: 32378542 [TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase. Lautala P; Ulmanen I; Taskinen J Mol Pharmacol; 2001 Feb; 59(2):393-402. PubMed ID: 11160877 [TBL] [Abstract][Full Text] [Related]
15. Kinetics and crystal structure of catechol-o-methyltransferase complex with co-substrate and a novel inhibitor with potential therapeutic application. Bonifácio MJ; Archer M; Rodrigues ML; Matias PM; Learmonth DA; Carrondo MA; Soares-Da-Silva P Mol Pharmacol; 2002 Oct; 62(4):795-805. PubMed ID: 12237326 [TBL] [Abstract][Full Text] [Related]
16. Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase. Vieira-Coelho MA; Soares-da-Silva P Brain Res; 1999 Mar; 821(1):69-78. PubMed ID: 10064789 [TBL] [Abstract][Full Text] [Related]
17. Synthesis of bridged catechol-homocysteine derivatives as potential inhibitors of catechol O-methyltransferase. Lever OW; Hyman C; White HL J Pharm Sci; 1984 Sep; 73(9):1241-4. PubMed ID: 6491941 [TBL] [Abstract][Full Text] [Related]
18. A structure-activity relationship study of catechol-O-methyltransferase inhibitors combining molecular docking and 3D QSAR methods. Tervo AJ; Nyrönen TH; Rönkkö T; Poso A J Comput Aided Mol Des; 2003 Dec; 17(12):797-810. PubMed ID: 15124929 [TBL] [Abstract][Full Text] [Related]
19. Kinetic inhibitory profile of BIA 3-202, a novel fast tight-binding, reversible and competitive catechol-O-methyltransferase inhibitor. Bonifácio MJ; Vieira-Coelho MA; Soares-da-Silva P Eur J Pharmacol; 2003 Jan; 460(2-3):163-70. PubMed ID: 12559377 [TBL] [Abstract][Full Text] [Related]
20. Prospecting for new catechol- da Silva IR; Parise MR; Pereira M; da Silva RA J Biomol Struct Dyn; 2021 Oct; 39(16):5872-5891. PubMed ID: 32691671 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]